195 related articles for article (PubMed ID: 17125961)
1. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.
Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ
Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961
[TBL] [Abstract][Full Text] [Related]
2. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.
Madjd Z; Parsons T; Watson NF; Spendlove I; Ellis I; Durrant LG
Breast Cancer Res; 2005; 7(5):R780-7. PubMed ID: 16168124
[TBL] [Abstract][Full Text] [Related]
3. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
[TBL] [Abstract][Full Text] [Related]
4. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
5. Loss of CD59 expression in breast tumours correlates with poor survival.
Madjd Z; Pinder SE; Paish C; Ellis IO; Carmichael J; Durrant LG
J Pathol; 2003 Aug; 200(5):633-9. PubMed ID: 12898600
[TBL] [Abstract][Full Text] [Related]
6. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.
Zhong XY; Zhang LH; Jia SQ; Shi T; Niu ZJ; Du H; Zhang GG; Hu Y; Lu AP; Li JY; Ji JF
Histopathology; 2008 Apr; 52(5):560-8. PubMed ID: 18312357
[TBL] [Abstract][Full Text] [Related]
7. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Lambie H; Miremadi A; Pinder SE; Bell JA; Wencyk P; Paish EC; Macmillan RD; Ellis IO
J Pathol; 2003 Jun; 200(2):207-13. PubMed ID: 12754741
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG; Douglas-Jones AG; Mansel RE
Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
12. Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.
Dales JP; Garcia S; Bonnier P; Duffaud F; Meunier-Carpentier S; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
Int J Oncol; 2003 Feb; 22(2):391-7. PubMed ID: 12527939
[TBL] [Abstract][Full Text] [Related]
13. The immunohistochemical detection of cripto-1 in benign and malignant human bladder.
Byrne RL; Autzen P; Birch P; Robinson MC; Gullick WJ; Neal DE; Hamdy FC
J Pathol; 1998 May; 185(1):108-11. PubMed ID: 9713367
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer.
Jensen V; Ladekarl M; Holm-Nielsen P; Melsen F; Soerensen FB
J Pathol; 1995 Aug; 176(4):343-52. PubMed ID: 7562249
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
17. Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients.
Schneider J; Romero H
Anticancer Res; 1995; 15(3):1117-21. PubMed ID: 7645934
[TBL] [Abstract][Full Text] [Related]
18. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma.
Kamal M; Shaaban AM; Zhang L; Walker C; Gray S; Thakker N; Toomes C; Speirs V; Bell SM
Breast Cancer Res Treat; 2010 Jun; 121(3):555-63. PubMed ID: 19669408
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
[TBL] [Abstract][Full Text] [Related]
20. Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas.
Hong SP; Lee EK; Park JY; Jeon TJ; Bang S; Park S; Chung JB; Lee WJ; Kim H; Song SY
Oncol Rep; 2009 Jan; 21(1):19-24. PubMed ID: 19082438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
